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ABSTRACT 
Aim: Frailty is a complex geriatric syndrome resulting in decreased physiological reserves. 
Frailty and polypharmacy are common in older adults and the focus of extensive studies, 
although little is known about the impact they may have on each other. This is the first 
systematic review analyzing the available evidence on the relationship between frailty and 
polypharmacy in older adults.  
Methods: Systematic review of quantitative studies. A comprehensive literature search for 
publications in English or Spanish was performed on MEDLINE, CINAHL, the Cochrane 
Database and PsycINFO in September 2017 without applying restrictions on the date of 
publication. Studies reporting any relationship between frailty and polypharmacy in older 
adults were considered.  
Results: A total of 25 publications were included, all of them observational studies. 
Evaluation of Fried´s frailty criteria was the most common approach, followed by the 
Edmonton Frail Scale and FRAIL scale. 16 of 18 cross-sectional analyses and 5 of 7 
longitudinal analyses demonstrated a significant association between an increased number of 
medications and frailty. The causal relation is unclear and appears to be bidirectional. Our 
analysis of published data suggests that polypharmacy could be a major contributor to the 
development of frailty.  
Conclusions: A reduction of polypharmacy could be a cautious strategy to prevent and 
manage frailty. Further research is needed to confirm the possible benefits of reducing 
polypharmacy in the development, reversion or delay of frailty.  
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1. INTRODUCTION 
 
Frailty is a complex geriatric syndrome resulting in decreased physiological reserves. 
Over the last few years, it has attracted increasing interest due to its direct relationship with 
adverse health effects such as physical and functional decline and increased mortality[1, 2]. 
There are different approaches to define and measure frailty, but all of them aim to identify or 
quantify vulnerability in older adults. There are two main established methods for the 
evaluation of frailty. i) Fried’s criteria[1], which define a clinical syndrome or phenotype, 
including weight loss, exhaustion, weak grip strength, slow walking speed and low physical 
activity; ii) The Frailty Index, first developed by Rockwood et al.[3], counts accumulated 
deficits of measures such as symptoms, signs, diseases and disabilities with the hypothesis 
that the more deficits a person has, the more likely that person is to be frail. This method 
considers frailty as a multidimensional risk state, and measures it by the quantity rather than 
by the nature of health problems. Sometimes a prefrail category is considered as a third 
intermediate clinical stage between robust and frail individuals[1].  
Similarly, polypharmacy or the use of multiple medications has also been categorized 
as a geriatric syndrome and it is frequently present in older adults[4]. Polypharmacy is a 
major issue of concern for its association with adverse health outcomes, including falls, 
functional impairment, adverse drug reactions, increased length of hospital stay, readmissions 
and mortality[5-7]. Multiple factors positively associated with polypharmacy like drug-drug 
interactions, drug-disease interactions or potentially inappropriate prescriptions may be 
involved in these adverse outcomes[8]. Thus, polypharmacy is considered an important and 
increasing challenge in clinical practice. 
Frailty and polypharmacy are common and widely studied entities in geriatric patients, 
although little is known about the impact they may have on each other[9]. It is possible to 
imagine a network of connections through which drugs and frailty might interact, including 
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physiological changes, multiple pathologies and chronic diseases, life expectancy, or 
functional or cognitive status. Frailty may influence a number of factors, including drugs 
pharmacokinetics and pharmacodynamics, toxicity, and their therapeutic efficacy. In turn, 
these factors may be involved in the development of frailty or in ways to prevent it. In the 
past few years, an increasing number of studies have tried to resolve and measure the 
relationship between frailty and polypharmacy and its underlying mechanisms. 
Here, we aim to analyze the available research evidence on the relationship between 
frailty and polypharmacy in older adults.  
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2. MATERIALS AND METHODS 
2.1 Search strategy  
The study was undertaken in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement[10] (see supplementary 
material) and the method used was based on the minimum criteria established by the 
Cochrane Back Review Group (CBRG)[11]. 
A scientific literature search was conducted in September 2017 to identify all relevant 
studies published in English or Spanish without applying date restrictions. Queries of the 
literature were performed using the electronic databases PubMed (MEDLINE), CINAHL 
(Cumulative Index to Nursing and Allied Health Literature), the Cochrane Library (DARE, 
HTA, EED, CDSR, CENTRAL), and PsycINFO. 
The literature search was designed with Medical Subject Headings (MeSH) terms for 
MEDLINE and adapted to the other databases according to their descriptors or by using 
keywords. A combination of the following search terms was used: (“frail elderly” or frail*) 
AND (“drug prescriptions” OR “drug therapy” OR “polypharmacy” OR “prescription drugs”). 
Also, the reference lists were examined to detect studies potentially eligible for inclusion.  
2.2 Selection criteria 
Original quantitative studies, regardless of their design, examining any relation 
between frailty and polypharmacy in older adults were included. Frailty had to be defined 
with a validated measurement tool, or a non-validated but available and well described one. 
Case reports, case series, single-case studies, conference proceedings, letters to the editor, 
dissertations, review articles or systematic reviews and meta-analyses were excluded. 
Authors were contacted to provide missing data when necessary. 
The exclusion criteria were as follows: 
- Studies with participants with mean age below 65 years. 
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- Studies focused exclusively on cancer, due to the unique features of the patients and 
the treatments used. 
2.3 Data extraction  
Two of our coauthors (MGV & NMV) independently screened the titles and abstracts 
of potentially eligible studies identified by the search strategy. If necessary, a third researcher 
(ACH) was consulted. Next, they examined the potentially eligible articles after a first 
evaluation of the whole text and selected those that met the inclusion standards for this 
review. The reviewers extracted relevant data from the selected articles, including study 
design, setting, number and characteristics of study participants, analyzed measurements, and 
outcomes. Outcome measures extracted from included studies are detailed in Table 1.  
2.4 Quality of the studies 
Two researchers assessed the quality of the studies and any differences were resolved 
by consensus. For longitudinal observational studies, the Newcastle-Ottawa Scale (NOS)[12] 
was used, and for cross-sectional studies a modified NOS (see Supplementary data) was used, 
as described in previous studies[13, 14]. The NOS assigns up to a maximum of nine points 
and the adapted NOS up to a maximum of 10, based on three quality parameters: selection, 
comparability, and outcome. 
 
2.5 Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY [15], and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 [16].  
RESULTS 
3.1 Search results 
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The search identified 1236 non-duplicated references, with 87 classified as potentially 
relevant after checking the titles and abstracts. After the screening of the full texts, 62 articles 
were excluded because they did not meet the inclusion criteria. Therefore, 25 publications 
were ultimately selected and included in the review[17-41] (Figure 1).  
3.2 Quality (risk of bias) 
All 25 publications included in the study were considered of acceptable quality. 
Studies assessed through NOS had a median score of 7.5 out of 9 (range: 6-8). Studies 
assessed through adapted NOS for cross-sectional studies had a median score of 8 out of 10 
(range: 6-9).The quality assessment of the included studies is shown in Figure 2.  
3.3 Characteristics of studies and participants 
All studies were published from 2009 until 2017 and only five were published more 
than five years ago. All the studies were observational; 11 were cross-sectional studies and 14 
were prospective cohort studies. However, in some of them, outcomes of interest for this 
review were obtained from cross-sectional analyses of baseline data [18, 19, 22, 28, 33, 34]. 
Different measurements or definitions of frailty were used: Fried´s criteria with various 
adjustments were the most used tool (in 14 studies), followed by the Edmonton Frail Scale (in 
four studies), the FRAIL scale (in three studies), the Frailty Index (in two studies) (FI, the 
Frailty index, based on Rockwood's cumulative deficits), and the Portuguese version of the 
Tilburg Frailty Indicator and the Groningen Frailty Indicator (in one study). Frailty cut-off 
scores varied depending on the method used for measurement. In some of the studies two 
groups of patients were defined (frail and robust/non-frail) and other studies included a third 
group, consisting of pre-frail subjects. Definitions of polypharmacy varied between studies, 
from more than three to more than six medications, but the most repeated definition is the use 
of five or more drugs. Some studies also defined a third category among polypharmacy 
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groups, when ten or more drugs were consumed: hyperpolypharmacy[24, 34-36] or excessive 
polypharmacy[26, 27, 38].  
Sample size ranged between 31 participants in Hilmer et al.[28] and 10,039 in Zheng 
et al.[41]. Most studies (n: 13) included patients aged 65 years or older and the cut-off age 
ranged from 50[35] to 80 years[38]. Based on previous data, the mean age varied noticeably 
between 69.6 years in Saum et al.[35] and 85.2 in Wang et al.[38]. The prevalence of frailty 
ranged between 6.2%[31] and 76%[25]. Regarding study setting, 13 studies included 
community-dwelling individuals, five studies included hospitalized patients in acute units and 
the rest included outpatients, care home residents or mixed populations. Participants had to 
meet specified inclusion criteria in some of the studies, like the use of statins [36] or 
disability[22]; or exclusion criteria, including shorter life expectancy[38, 39], severe 
cognitive[21, 33] or functional[36] impairment, or the presence of cancer or other advanced 
diseases[33].  
3.4 Objectives and measurements analyzed 
The objectives and variables of the studies included in this review were heterogeneous. Most 
of the studies provide outcomes of interest in a circumstantial way when describing their 
participant characteristics, and only some studies were aimed at analysing the possible 
association or interaction between frailty and polypharmacy or the number of medications 
used[21, 23, 24, 26, 27, 29, 35, 37-39, 41].  The included studies present a wide range of 
outcome measures of interest. The most important ones are shown in Table 1. 
3.4.1 Frailty and polypharmacy/number of drugs 
Eighteen cross-sectional analyses assessed the link between polypharmacy and frailty status 
in various populations, and sixteen of them demonstrated a significant association. From 
seven longitudinal analyses, five demonstrated significant associations. Table 2 summarizes 
the most relevant characteristics and outcomes extracted from included studies. Most of the 
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results come from cross-sectional studies. Several studies show that the mean drug 
consumption by frail patients is higher than that of robust ones[17, 18, 26, 28, 30, 36, 40], 
although in Perera et al.[33] the difference was not statistically significant for a group of 
hospitalized patients aged ≥ 70 years with atrial fibrillation. Gnjidic et al. (2012a) established 
that the optimal discriminating number of concomitant medications associated with the 
presence of frailty was 6.5[23]. Other studies revealed that the prevalence of frailty was 
higher among patients with polypharmacy or hyperpolypharmacy (≥10 drugs)[20, 24, 35]. 
This was not the case in the study by Wang et al.[38] in which an inverse relation was 
determined with a sample of 1592 men aged ≥ 80 years. Another study by Gnjidic et al. 
(2012b) also showed a greater prevalence of prefrailty in increasing polypharmacy 
groups[24].  
Furthermore, several studies show the likelihood of being frail increasing with every 
medication added to the treatment (OR between 1.13 and 1.20)[20, 23, 26], with 
polypharmacy (OR between 1.77 and 2.55)[24, 26, 32, 35], and with hyperpolypharmacy 
(OR between 4.47 and 5.8)[24, 26, 35]. Some of these studies report the same results when 
the status of prefrailty was examined[26, 35], although the relationship was not always linear 
when the three groups (robust, prefrail, frail) were considered[26]. In another study by 
Coelho et al.[21], the association was found only with the physical frailty domain, and no 
with psychological and social domains. Additionally, the relation between frailty and the use 
of a larger number of drugs was not significant in analyses with more complex multivariate 
regression models including the type of medication used. Herr et al. show that polypharmacy 
was associated with the number of frailty criteria in models adjusted for socio-demographic 
and health characteristics in a French representative study with people aged 65 years or 
older[27].  Poudel et al.  and Hasan et al. [25, 34] identified an increase in the mean frailty 
index and Groningen Frailty Indicator associated to polypharmacy category: 
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(hyperpolypharmacy>) polypharmacy>no polypharmacy. Similarly, Crentsil et al. [22] 
reported a higher probability of consuming more medications in association with frailty (OR 
1.10). Bonaga et al. and Merchant et al. [19, 31] showed that the prevalence of polypharmacy 
was higher in frail patients. Furthermore, Thai et al. [36] show the same trend with 
polypharmacy and hyperpolypharmacy, but without statistically significant differences.  
Regarding longitudinal studies, Woo et al. (2014) [39] did not find statistically significant 
differences in the incidence of polypharmacy (≥ 4) after four years according to baseline 
frailty. Other studies with a prospective design showed a higher incidence of frailty or 
probability of becoming frail when a larger number of drugs was taken[38] or with the 
presence of polypharmacy/hyperpolypharmacy[24, 35, 41]. However, Jamsen et al. [29] did 
not find a relationship between the use of a larger number of drugs and transitions to 
prefrailty or frailty state after a five-year follow-up period. Trevisan et al. [37], found an 
association between transitions to prefrailty or frailty and the use of > 3 drugs with a 
univariate analysis, but not with a multivariate analysis after a four-year follow-up.  
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4. DISCUSSION 
Here, we aim to summarize the evidence available to date on the relationship between 
frailty and polypharmacy in older adults. To the best of our knowledge, this is the first 
systematic review evaluating this relevant health issue. Frailty is a recent concept that is 
increasingly attracting interest, as evidenced by the contemporaneity of most of the 
publications evaluated.  
Many different outcome measures regarding the interaction between frailty and 
polypharmacy have been examined, yielding a large amount of information. However, the 
observational design of the studies did not allow for the analysis of high-quality evidence. 
Nevertheless, the association between frailty and polypharmacy in older people seems clear, 
despite the various study designs, measurements, or patient groups evaluated.  
The first difficulty encountered when analyzing the ensemble of selected studies was 
the lack of homogeneity in the definition and quantification of frailty. The different scales 
used and their underlying concepts lead to a wide variability in the calculation of prevalence 
and incidence of frailty, prefrailty and of all outcomes associated with these syndromes[42]. 
Additionally, different study settings, age ranges and pathologies of the participants, or 
differences in inclusion or exclusion criteria may influence the results and conclusions of 
every study.  
 The association between frailty and polypharmacy seems so evident that even some 
scales or tools to measure frailty, including the Edmonton Frail Scale, the Groningen Frailty 
Indicator or some versions of Frailty Index include the consumption of drugs. To properly 
examine the relationship between polypharmacy and frailty, the number of medications used 
should have been excluded for assessing frailty status, as done in the study by Poudel et 
al.[34]. 
 This article is protected by copyright. All rights reserved. 
Although polypharmacy is a widespread concept, there is not a single and clear 
definition for it[43]. Different definitions of polypharmacy of included studies (from > 3 to ≥ 
6)[32, 37] may lead to confusion and difficulty when comparing results and drawing general 
conclusions. A low threshold for defining polypharmacy could explain the difficulty to 
demonstrate a significant association between polypharmacy and frailty. For example 
Trevisan et al. [37] did not find an association between transitions to prefrailty or frailty and 
the use of > 3 drugs with a multivariate analysis. This could be a consequence of selecting the 
low threshold of 3 drugs. In a sample of community-dwelling men aged ≥ 70 years in 
Australia, Gnjidic et al. [23] defined a cut-off score of 6.5 drugs as the best discriminatory 
number for frailty. Moulis et al. [44] presented a similar analysis with men and women aged 
≥ 65 years in France, reporting a cut-off score of ≥ 6 drugs. It may be interesting to assume 
this threshold to standardize the definition of polypharmacy in future studies about the 
relationship of polypharmacy and frailty, or to use the mean number of drugs instead of a cut-
off.  
 Another possible limitation of our analysis of published data is the fact that most of 
the studies were not designed to determine the association between frailty and polypharmacy 
(it was not the primary outcome). Thus, the sample size of some of the studies may not 
provide enough power to find significant associations. From the four publications that did not 
find any association between frailty and polypharmacy[29, 33, 36, 39], two of them did not 
describe it among their objectives, and had small sample sizes (180 and 220)[33, 36]. Jamsen 
et al. and Woo et al. [29, 39] had the association between frailty and polypharmacy as a 
primary outcome, and have large sample sizes (1705 and 4000 participants). It should be 
noted that results from Jamsen et al., Gnjidic et al 2012(a) and Gnjidic et al 2012(b) come 
from the same pool of participants, and that Bennett et al., Hilmer et al., Perera et al. and Thai 
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et al. all use small inpatient cohorts from the same hospital.  Repeated analyses within the 
same or similar populations do not provide additional evidence.   
Despite the obvious association, it is difficult to establish causality and determine 
what occurs first: frailty or polypharmacy. Longitudinal studies measuring the impact of 
polypharmacy in the incidence of frailty could be important in this regard. Several studies 
reported a higher probability of becoming frail over time in patients with polypharmacy[24, 
35, 41], although in another study this association was not maintained following a 
multivariate analysis[37]. A recent study by Veronese et al. [45], that has not been selected 
for this review because it included younger individuals, showed after a 8-year follow-up of 
4402 participants at baseline, that use of 4-6 medications had a higher risk of developing 
frailty. Those using more than seven drugs were at even higher risk. Wang et al. [38] 
concluded that the risk of developing frailty increases with the number of medications taken, 
although Jamsen et al. did not achieve conclusive results in a similar analysis after a five-year 
follow-up period [29] . Of note, all these studies used adjusted models including comorbidity 
as a covariate (comorbidity indexes or presence or number of different chronic diseases). 
Thus, comorbidities may not be the only cause of increased risk of frailty associated to 
polypharmacy. Conversely, Woo et al. assessed the incidence of polypharmacy over time 
according to frailty status but no clear association was identified [39]. The relationship 
between frailty and polypharmacy has also been addressed in animal models. Huizer-Pajkos 
et al. [46] performed an interventional mouse study of short-term polypharmacy that showed 
a non-significant trend towards increased frailty index after 2-4 weeks of administering 
polypharmacy in the diet. 
The association of frailty and polypharmacy may be complex and bidirectional. On 
the one hand, frailty is linked to certain chronic diseases and multimorbidity[47], which can 
consequently lead to polypharmacy. On the other hand, there are plausible mechanisms by 
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which drugs may affect the development of frailty. As indicated by Gnjidic and Hilmer[48], 
several elements that may be considered clinical components or characteristics of frailty have 
been directly linked with the number of drugs taken, including weight loss, balance disorders, 
poor nutritional status, or functional deterioration[49, 50]. The available evidence so far does 
not allow to confirm which of these elements are involved in the pathogenesis of frailty 
associated with polypharmacy. However, polypharmacy may be recognized as a major 
contributor to the development of frailty. Thus, reducing polypharmacy in older adults has 
been suggested as a recommended measure for both prevention and management of 
frailty[51]. Further studies should be carried out in the future to confirm the possible benefits 
of reducing polypharmacy in the development, reversion or delay of frailty. 
Furthermore, the consumption of a greater number of drugs is associated with an 
increase in other negative medication-related variables like drug-drug interactions, potentially 
inappropriate prescribing, anticholinergic burden of treatments or adverse drug reactions[52-
54]. This may explain why some studies have found a higher proportion of these factors in 
frail older people, and suggest other possible mechanisms by which polypharmacy interferes 
with frailty[18, 24, 29, 32, 36, 55, 56].  
In addition to the reciprocal impact that frailty and polypharmacy may have on each 
other, some studies suggest that they can act as modulators for their negative effect in health 
outcomes, so their interaction could determine the frequency of some health related adverse 
events. Bonaga et al. [19] showed that polypharmacy was associated with an increased risk of 
adverse events (disability, hospitalization, emergency department visits and mortality)  in 
prefrail and frail older adults, but not in non-frail individuals. Herr et al. showed that 
excessive polypharmacy and frailty are independent risk factors for mortality, but the 
combination of both multiplied by 6.30 the risk of dying during a 2.6 year-follow-up 
period[26].  
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It is also worth noting that the relationship between frailty and medications is a very 
complex issue. There seems to be a stronger association between frailty and changes in 
pharmacokinetic responses, specially metabolism and excretion, than with chronological 
age[17, 28]. This could also contribute to a higher risk of adverse drug reactions and toxicity 
in frail older people. Older people seem to have an increased sensitivity to certain drugs, but 
the evidence of the possible influence of frailty on pharmacodynamics and efficacy is 
scarce[18, 57, 58], although plausible due to physiological changes[59]. Moreover, as a 
predictor of clinical outcomes and limited life expectancy, frailty may modify the goals of 
health care and its priorities, and influence decision-making regarding the use of 
medicines[21, 56]. These issues have been addressed more in depth in other publications[59, 
60].  
Finally, our study has some potential limitations. Despite the comprehensive search 
strategy, the heterogeneity of terms and definitions of frailty and polypharmacy may have 
affected the sensitivity of the search because some plausible data of interest could not be the 
primary outcome of the studies. Different studies comparing frail and non-frail participants 
including polypharmacy in the baseline characteristics may have been missed. However, the 
selection bias should not affect most relevant studies evaluating the relationship between 
frailty and polypharmacy as a primary outcome. 
  
5. CONCLUSIONS 
Results from this review suggest that polypharmacy is associated with frailty in older 
people, although the causal relation is unclear and, in fact, appears to be bidirectional. The 
lack of standardized definitions for frailty and polypharmacy hinders research in this area and 
leads to a wide range of outcomes. There is still scarce evidence of the mechanisms involved, 
and it is difficult to form conclusions on clinical practice based on the observational studies 
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available at the moment. However, polypharmacy may be recognized as a major contributor 
to the development of frailty. It seems clear that frailty is an important issue that must be 
taken into account for decision-making in drug prescribing to older patients, and that 
polypharmacy should be assessed with special caution in frail older adults. Therefore, it has 
been suggested that a reduction of polypharmacy could be a strategy to prevent and manage 
frailty. Further research is needed to confirm the possible benefits of reducing polypharmacy 
in the development, reversion or delay of frailty. 
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Table 1. List of outcome measures extracted from included studies 
Outcomes of interest Measures/Units Studies 
Correlation between number of 
medications/polypharmacy groups and level of 
frailty  
Regression coefficient (b) 
Semi-partial correlation 
coefficient (r) 
OR 
IRR 
Coelho et al., Crentsil et 
al., Hasan et al., Herr et 
al. 2017 
Average number of medications according to frailty 
status 
Number of medications 
Ballew et al., Bennett et 
al., Herr et al. 2015, 
Hilmer et al., Jung et al., 
Perera et al., Thai et al., 
Woo et al. 2015 
Average frailty score according to polypharmacy 
group 
 
frailty score Hasan et al., Poudel et al. 
Prevalence of polypharmacy according frailty 
status 
% participants 
OR 
Bonaga et al., Merchant et 
al., Thai et al. 
Prevalence of frailty according to polypharmacy 
group/number of drugs 
% participants 
OR 
Castell et al., Gnjidic et 
al.(a), Gnjidic et al.(b), 
Herr et al. 2015, Moulis et 
al., Saum et al., Wang et 
al. 
Incidence of polypharmacy according to frailty 
status 
% participants 
OR 
Woo et al. 2014 
Incidence of frailty according to polypharmacy 
group/ number of drugs 
% participants 
OR 
Gnjidic et al.(a), Saum et 
al., Wang et al., Zheng et 
al.  
Transitions between frailty states according to 
polypharmacy group/ number of drugs 
HR 
OR 
Jamsen et al., Trevisan et 
al. 
HR: hazard ratio; IRR: incidence rate ratio; OR: odds ratio 
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Table 2. Characteristics and main outcomes of included studies 
Authors,  
year 
Design of 
the study 
Country/ 
setting 
Characteristics of 
the participants 
Definition of 
frailty 
Measurements Outcomes 
Ballew et al., 
2017 
Cross-
sectional 
study 
USA. 
Community-
dwelling 
4987 >65 years 
NF 75.4 ± 5.1 
F 78.0 ± 5.6 
Fried 
 ≥ 3: frail 
Average number of drugs 
according to frailty status 
Non-frail 8.8 ± 4.6 vs frail 10.5 ± 5.0 
Bennett et al., 
2014 
Cohort 
study, cross-
sectional 
analysis of 
baseline data 
for outcomes 
of interest 
Australia. 
Hospitalized 
204 ≥ 60 years.  
80.5 ± 8.3 years 
65% female 
Reported 
Edmonton 
Frail Scale  
≥ 8: frail 
Average number of drugs 
according to frailty status 
At admission (non-frail 4.4 ± 3.3 vs frail 9.8 ± 
4.3)  
At discharge (NF 4.9 ± 3.3 vs F 10.3 ± 4.2) 
 (p < 0.0001) 
Bonaga et al., 
2017 
Cohort 
study, cross-
sectional 
analysis of 
baseline data 
for outcomes 
of interest 
Spain.  
Population 
based 
 
773≥ 70 years 
78.5±5.8 years 
59.1% female 
Fried 
0: non-frail 
1-2: prefrail 
≥ 3: frail 
Prevalence of polypharmacy (≥ 
5 drugs) according to frailty 
status  
Non-frail 40.2% vs prefrail 63.5% vs frail 
81.9% 
 
Castell et al., 
2013 
Cross-
sectional 
study 
Spain. 
Urban 
population in 
primary care 
1 327 ≥ 65 years 
75.4 ± 7.4 years 
53.4% female 
Fried 
 ≥ 3: frail 
-Prevalence of frailty according 
polypharmacy groups (≥ 5 
drugs) 
-OR for frailty according to 
increasing number of drugs 
(higher for each additional drug) 
With polypharmacy: 14.9%; without 
polypharmacy: 4.9%; p < 0.001 
 
OR:1.17 (95% CI 1.08-1.26)  
Coelho et al., 
2015 
Cross-
sectional 
study 
Portugal. 
Community-
dwelling 
252 ≥ 65 years 
79.2 ±7.3 years 
75.8% female 
 
Tilburg Frailty 
Indicator 
(TFI) 
Portuguese 
version. 
 (0-15) 
Association between number of 
drugs and frailty by a 
hierarchical multiple regression 
analysis 
Regression coefficient: 0.20 (p<0.001) (95% CI 
0.08-0.3) 
Semi-partial correlation coefficient: 0.16 
Higher number of drugs is associated to greater 
levels of frailty (not maintained when drug type 
is introduced in the regression model) 
Crentsil et al., 
2010 
Cohort 
study, cross-
sectional 
analysis of 
baseline data 
USA. 
Community-
dwelling 
1 002 disabled 
women ≥ 65 years 
78.3 ±8.1 years 
Fried  
≥ 3: frail 
<3: non-frail 
OR for the use of a larger 
number of drugs according to 
the presence of frailty 
OR:1.10 (95% CI 1.01-1.20) 
 
Gnjidic et al., Cohort study Australia. 1 705 men ≥ 70 years Fried -Cut-off drug score for presence Cut-off score: 6.5 drugs 
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2012a Community-
dwelling 
76.9 ±5.5 years 
 
0: non-frail 
1-2: prefrail 
≥ 3: frail 
of frailty:  
-OR for frailty according 
increasing number of drugs 
(higher for each additional drug) 
 
OR 1.13 (95% CI 1.06-1.21) (p = 0.0002) 
 
Gnjidic et al., 
2012b 
Cohort study Australia. 
Community-
dwelling 
1 662 men ≥ 70 years 
76.9 ±5.4 years 
 
Fried 
0: non-frail 
1-2: prefrail 
≥ 3: frail 
-Prevalence of prefrailty and 
frailty according to 
polypharmacy group  
-OR for frailty according to  
polypharmacy group 
 
-Incidence of frailty at two 
years: OR for frailty according 
to polypharmacy group  
Robust/prefrail/frail (%) (p < 0.0001) 
Polypharmacy (≥ 5) 27.2/44.4/64.7 
Hyperpolypharmacy (≥ 10) 1.9/5.3/17.3 
Polypharmacy OR 2.55 (95% CI 1.69-3.84)  
Hyperpolypharmacy OR 5.80 (95% CI 2.90-
11.61)  
 
Polypharmacy OR 2.45 (95% CI 1.42-4.23)  
Hyperpolypharmacy OR 2.5 (95% CI 0.76-8.26)  
Hasan et al., 
2017 
Cross-
sectional 
study 
Malaysia. 
Care home 
residents 
202 ≥ 65 years 
76.8±7.8 years 
62% female 
 
Groningen 
Frailty 
Indicator 
(GFI) 
≥ 4: frail 
-Average GFI score according 
to polypharmacy group 
-Relationship between GFI and 
number of medications used per 
participant 
With polypharmacy: 7.2±3.4 / Without 
polypharmacy: 5.7±3.6 (p=0.002) 
Significantly and positively correlated (r=0.21, 
p=.002)  
Herr et al., 
2015 
Cross-
sectional 
study 
France 
Community-
dwelling 
2 350 ≥ 70 years 
83.3 ±7.5 years 
59.4% female 
 
Fried 
1-2: prefrail 
≥ 3: frail 
- Average number of drugs 
according to frailty status 
- For each additional drug: 
OR for pre-frailty  
OR for frailty 
- According to the presence of 
polypharmacy (5-9) 
OR for pre-frailty 
OR for frailty 
- According to the presence of 
excessive polypharmacy (≥ 10) 
OR for pre-frailty   
OR for frailty 
Non-frail/prefrail/frail: 
4.6/6.1/7.1 (p < 0.001) 
 
OR 1.12 (95% CI 1.07-1.17)  
OR 1.20 (95% CI 1.12-1.28) 
 
 
OR 1.82 (95% CI 1.44-2.37)  
OR 1.77 (95% CI 1.20-2.61) 
 
 
OR 2.51 (95% CI 1.49-4.23)  
OR 4.47 (95% CI 2.37-8.42) 
Herr et al., 
2017 
Cross-
sectional 
study 
France 
Community-
dwelling 
1890≥ 65 years 
74.7±7.4 years 
60.5% female 
Fried 
≥ 3: frail 
IRR number of frailty criteria- 
polypharmacy  
5–9 vs 0–4 drugs 
10+ vs 0–4 drugs 
 
 
1.587 (p<0.001). With confounders 1.163 
(p<0.05) 
2.710 (p<0.001). With confounders 1.451 
(p<0.001) 
Hilmer et al., Cohort Australia 31≥ 65 years Reported Average number of drugs Frail 4.6±2.0 vs non-frail 2.1±1.8 (p=0.001) 
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2011 study, cross-
sectional 
analysis of 
baseline data 
for outcomes 
of interest 
Hospitalized 77.0±7.1 years 
19.4% female 
Edmonton 
Frail Scale 
≥8: frail 
<8: not frail  
according to frailty status   
Jamsen et al., 
2016 
Cohort study Australia. 
Community-
dwelling 
1 705 men ≥ 70 years 
76.9 ±5.5 years 
 
Fried 
0: robust 
1-2: prefrail 
≥ 3: frail 
HR for transition to a state of  
- prefrailty  
- frailty  
by increasing number of drugs 
 
HR 1.04 (95% CI 1.00-1.09) 
HR 1.06 (95% CI 0.99-1.13) 
Jung et al., 
2016 
Cross-
sectional 
study 
Korea. 
Outpatient and 
impatient 
103≥ 65 years 
76.8 ± 6.1 years 
46.6% female 
FRAIL scale 
(Korean 
version) 
0: robust 
1-2: prefrail 
≥ 3: frail 
Average number of drugs 
according to frailty status 
Robust 5.4 ± 3.7 vs  prefrail 6.4±4.4 vs frail 
9.0±4.3 (p=0.014) 
Merchant et 
al.,  
2017 
Cross-
sectional 
study 
Singapore.  
Community-
dwelling 
1051 
71.2 years 
57.2% female 
FRAIL scale 
1-2: prefrail 
≥ 3: frail 
Prevalence of polypharmacy (≥ 
5) according to frailty status  
Robust 18.1%, prefrail 29.8%, frail 41.5% 
(p<0.001) 
Moulis et al., 
2015 
Cross-
sectional 
study 
France. 
Outpatient 
437 ≥ 65 years 
83.05 ± 6.5 years 
62.7% female 
Fried 
1-2: prefrail  
≥ 3: frail 
OR for frailty according to the 
presence of polypharmacy (≥ 6) 
OR 1.85 (95% CI 1.21-2.82. p < 0.02) 
 
Perera et al., 
2009 
Cohort 
study, cross-
sectional 
analysis of 
baseline data 
for outcomes 
of interest  
Australia. 
Hospitalized 
220 ≥ 70 years 82.7 ± 
6.3 years 
54% female 
 
Edmonton 
Frail Scale 
Average number of drugs 
according to frailty status  
Frail 8.2±3.2 vs non-frail 7.8±3.6 (p NS) 
 
Poudel et al., 
2016 
Cohort 
study, cross-
sectional 
analysis of 
baseline data 
for outcomes 
of interest 
Australia. 
Hospitalized 
1 418 ≥ 70 years 
81.0 ± 6.8 years 
55% female 
Frailty index  
Low: 0-0.25 
Mean: 0.26-
0.39 
High: ≥ 0.4 
Average FI according to 
polypharmacy group 
0-4 drugs FI 0.30±0.17 
5-9 FI 0.32±0.15 
≥ 10 FI 0.34±0.13  
 (p = 0.003) 
Saum et al., 
2016 
Cohort study Germany. 
Community-
3 058 patients (50-75 
years) 
Fried 
0: non-frail 
- Prevalence of frailty according 
to polypharmacy group 
Hyperpolypharmacy (≥ 10): 24.9% 
Polypharmacy (5-9) 12.1%. No polypharmacy 
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dwelling 69.6±6.3 years 
52.4% female 
1-2: prefrail  
≥ 3: frail 
 
- OR for pre-frailty according to 
the presence of  
 polypharmacy 
 hyperpolypharmacy  
- OR for frailty according to the 
presence of 
 polypharmacy 
 hyperpolypharmacy  
- Incidence of frailty by 
polypharmacy group 
- OR for incident prefrailty 
according to the presence of 
 polypharmacy 
 hyperpolypharmacy  
- OR for incident frailty 
according to the presence of  
 polypharmacy 
 hyperpolypharmacy  
(0-4) 3.7% (p < 0.01) 
 
OR 1.20 (95% CI 1.00-1.44) 
OR 1.48 (95% CI 1.03-2.14) 
 
 
OR 2.30 (95% CI 1.60-3.31) 
OR 4.97 (95% CI 2.97-8.32) 
No polypharmacy: 5.8%; polypharmacy: 13.0%, 
hyperpolypharmacy 19.3% 
 
 
OR 1.33 (95% CI 1.05-1.67) 
OR 1.86 (95% CI 1.11-3.10) 
 
 
OR 1.85 (95% CI 1.24-2.76) 
OR 3.08 (95% CI 1.55-6.12) 
Thai et al., 
2015 
Cross-
sectional 
study 
Australia. 
Hospitalized 
(acute) 
180 patients ≥ 65 
years, 
Median 78 years 
(IQR=14) 
47.2% female 
 
Reported 
Edmonton 
Frail Scale 
0-7: robust 
≥ 8: frail 
 
- Average number of drugs 
according to frailty status 
- Prevalence of polypharmacy 
(≥ 5 drugs) according to frailty 
status  
- Prevalence of 5-9 drugs 
according to frailty status 
- Prevalence of 
hyperpolypharmacy (≥ 10 
drugs) according to frailty status 
Robust 8 (IQR 4) vs frail 9 (IQR 5) 
 
R 92.3% vs F 96.9% 
 
 
R 64.1% vs F 54.0% 
 
R 28.2% vs F 42.9%. p = 0.095  
 
Trevisan et 
al., 2016 
Cohort study Italy. 
Outpatient 
2 925 patients ≥ 65 
years 
74.4 ±7.3 years 
59.7% female 
Fried 
1-2: prefrail  
≥ 3: frail 
OR for transitions to prefrailty 
or frailty status according to use 
of > 3 drugs 
Univariate analysis: 
OR from non-frail: 1.24 (1.13-1.37) (p<0.0001) 
OR from prefrail: 1.55 (1.39-1.73) (p<0.0001) 
Multivariate analysis: 
OR from non-frail: 1.05 (0.94-1.17)  
OR from prefrail: 1.04 (0.92-1.18) 
Wang et al., 
2015 
Cohort study 
 
China. 
Outpatient 
1 592 men ≥ 80 years 
85.2 (80-104) years 
 
Fried 
≥ 3: frail 
 
-Prevalence of frailty according 
to baseline polypharmacy group 
 
-Prevalence of frailty according 
to polypharmacy group at five 
No polypharmacy (0-5): 30.5%, polypharmacy 
(6-9): 29.3%, excessive polypharmacy (≥ 10): 
29.6% (p = 0.261). 
No polypharmacy: 42.7%, polypharmacy: 
34.2%, excessive polypharmacy: 33.7% (p < 
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years 
- OR for incident frailty 
according to increasing number 
of drugs 
0.05). 
OR 1.06 (95% CI 1.02-1.11)  
 
Woo et al., 
2014 
Cohort study Hong Kong. 
Community-
dwelling 
4 000 patients ≥ 65 
years 
 
Fried 
1-2: prefrail  
≥ 3: frail 
 
-Prevalence of polypharmacy (≥ 
4) after a follow-up period 
according to baseline frailty 
status 
-OR for polypharmacy after a 
follow-up according to baseline 
frailty status 
Robust: 13.7%; prefrail: 18.9%; frail 21.5% (p = 
0.7036).  
 
OR according to two models: 
1.36 (95% CI 0.72-2.56). 1.30 (95% CI 0.68-
2.48)  
Woo et al., 
2015 
Cross-
sectional 
study  
Hong Kong. 
Community-
dwelling 
816 ≥ 65 years 
58.9% ≥ 75 years 
85.4% female 
FRAIL Scale 
0: robust 
1-2: prefrail  
≥ 3: frail 
Average number of drugs 
according to frailty status 
Frail 4.3 ± 2.9; non-frail 2.9 ± 2.2 (p = 0.001) 
 
Zheng et al., 
2016 
Secondary 
analysis of a 
cohort study 
China 
Community-
dwelling 
10 039 ≥ 55 years 
70.5 ± 7.8 years  
61.3% female 
 
FI 34 items 
Frailty  
FI ≥ 0.25 
OR for incident frailty 
according to the presence of 
polypharmacy (≥ 4 drugs) 
Adjusted OR =1.37 (p < 0.05). 
 
 
CI: confidence interval; F: frail; FI: frailty index; HR: hazard ratio; IQR: interquartile range; IRR: incidence rate ratio; NF: non-frail; NS: non-significant; OR: odds ratio; R: 
robust 
* Results from Gnjidic et al 2012(a), Gnjidic et al 2012(b) and Jamsen et al. 2016 come from the same pool of participants (Concord Health and Aging in Men Project, CHAMP) 
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Figure 1. Flowchart of the selection process of study publications 
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Figure 2a.   Newcastle-Ottawa Quality Assessment Scale for exposure and outcome of 
interest in cohort-studies  
Figure 2b.   Modified Newcastle-Ottawa Quality Assessment Scale for exposure and outcome 
of interest in cross-sectional studies 
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Hyperlinks 
 
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=
639#Inhibitors 
 
